New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients

Source :: PR Newswire. August 12, 2020
Publication Year :: 2020
Abstract: - Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are [...]

Subjects :: Allergan PLC -- Product development
Roche Holding AG -- Product development
Medical research
Medicine, Experimental
Biotechnology industry -- Product development
Clinical trials
Chemotherapy
Cancer -- Chemotherapy
Pharmaceutical industry -- Product development
Business
News, opinion and commentary
Venclexta (Medication) -- Product development

Tools